date:Sep 13, 2012
utrition RD director Yael Lifshitz said the clinical trials plan represents Enzymotec's ongoing dedication to study the special characteristics of human milk and demonstrate its lipid-based ingredients' health benefits on various infant populations.
We developed this innovative ingredient and educated the premium infant formula market over the last several years. Enzymotec invested 10% of its revenue in research and development-a percentage considered among the highest in the industry, Lifshitz